This article is more than 5 years old. Information may no longer be current.
Motegrity now available in the U.S. for adults with chronic idiopathic constipation
Click Here to Manage Email Alerts
Motegrity, a once-daily, oral selective serotonin-4 receptor agonist, is now available via prescription in the U.S. for adults with chronic idiopathic constipation, according to a company press release.
The FDA in December approved Motegrity (prucalopride, Takeda).
“There is a significant unmet patient need for adults living with chronic idiopathic constipation in the United States,” Tom Koutsavlis, head of Takeda’s U.S. medical office, said in the release. “Takeda is committed to bringing innovative solutions to patients and GI is one of our key therapeutic areas.”
The most common adverse events that have been reported in previous trials include headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence and fatigue.